UKC Ljubljana

Tirzepatide Shows Promise for Weight Loss and Brown Adipose Tissue Activation in Obesity Treatment

- A new clinical trial is investigating tirzepatide's effects on brown adipose tissue activity and volume in adults with obesity, using advanced imaging techniques including 18F-FDG-PET/CT, MRI, and infrared thermography over 24 weeks. - Cochrane review evidence confirms tirzepatide likely results in significant weight loss in the medium term (up to 1.5 years) and maintains this effect long-term (around 3.5 years) compared to placebo. - The drug may increase non-serious side effects but shows little difference in serious adverse events, with potential benefits for thermogenic energy expenditure through novel mechanisms beyond caloric restriction.